Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B O'Brien

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Digestive Diseases and Sciences|September 25, 2004
Beneficial effects of topical testosterone replacement in patients with end-stage liver diseaseGuy W Neff, Christopher B O'Brien, Marzia Montalbano, et al.
Cancers|June 28, 2023
Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver TransplantJoao Manzi, Camilla O Hoff, Raphaella Ferreira, et al.
Journal of Hepatology|February 21, 2006
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis CDaniele Prati, Mitchell L Shiffman, Moisés Diago, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2025
Dose-dependent, opioid-induced sleep disruption is partially mediated by motor activity but not by body temperature in C57BL/6J miceDiana Zebadúa Unzaga, Christopher B O'Brien, Natania W Cooper, et al.
Gastroenterology|December 4, 2004
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem, Moisés Diago, Edward Gane, et al.
The American Journal of Gastroenterology|August 23, 2002
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver diseaseGuy W Neff, Christopher B O'Brien, K Rajender Reddy, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 22, 2004
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decadeGuy W Neff, Christopher B O'brien, Jose Nery, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 27, 2004
Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testingGuy W Neff, Christopher B O'Brien, Robert Cirocco, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 24, 2004
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infectionGuy W Neff, Christopher B O'Brien, Jose Nery, et al.
The Annals of Pharmacotherapy|October 28, 2004
Tenofovir therapy for lamivudine resistance following liver transplantationGuy W Neff, Jose Nery, Daryl Ty Lau, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Digestive Diseases and Sciences|September 25, 2004
Beneficial effects of topical testosterone replacement in patients with end-stage liver diseaseGuy W Neff, Christopher B O'Brien, Marzia Montalbano, et al.
Cancers|June 28, 2023
Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver TransplantJoao Manzi, Camilla O Hoff, Raphaella Ferreira, et al.
Journal of Hepatology|February 21, 2006
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis CDaniele Prati, Mitchell L Shiffman, Moisés Diago, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2025
Dose-dependent, opioid-induced sleep disruption is partially mediated by motor activity but not by body temperature in C57BL/6J miceDiana Zebadúa Unzaga, Christopher B O'Brien, Natania W Cooper, et al.
Gastroenterology|December 4, 2004
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem, Moisés Diago, Edward Gane, et al.
The American Journal of Gastroenterology|August 23, 2002
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver diseaseGuy W Neff, Christopher B O'Brien, K Rajender Reddy, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 22, 2004
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decadeGuy W Neff, Christopher B O'brien, Jose Nery, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 27, 2004
Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testingGuy W Neff, Christopher B O'Brien, Robert Cirocco, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 24, 2004
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infectionGuy W Neff, Christopher B O'Brien, Jose Nery, et al.
The Annals of Pharmacotherapy|October 28, 2004
Tenofovir therapy for lamivudine resistance following liver transplantationGuy W Neff, Jose Nery, Daryl Ty Lau, et al.
Pageof 3